SKYSCRAPER-03

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Jan 10, 2022 → Sep 11, 2026

Cited window

Jan 10, 2022 → Aug 23, 2026

Retrieved

Oct 31, 2026

Title

A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation

Registry

NCT04513925

Study IDs

GO41854 · 2019-004773-29

Sponsor

Hoffmann-La Roche

Design

Phase 3 · Interventional, randomized, parallel

Status

Completed

Enrollment

829 actual

Registered

2020-08-14

Start

2020-08-24 actual

Primary completion

2025-05-27 actual

Primary endpoint

Progression-free Survival (PFS), as Assessed by an Independent Review Facility (IRF) in Programmed Death-ligand 1 (PD-L1) Positive Analysis Set (PPAS)

Interventions

3 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Not yet captured in this edition: a view on radiotherapy’s immune effects and alternative ways to combine immunotherapy with radiotherapy.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –67 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed for this edition do not represent all HCPs or all public discussion; frequencies and consensus cannot be estimated.
• –Some additional passages were not fully assessed, and discussion using unnamed references or different spellings may be missing.
• –Organizational accounts, relayed publications or presentations, repeated posts and multiple versions of one episode do not establish additional independent HCP views.
• –A remark about continued tiragolumab development cannot be assigned reliably to a speaker across the podcast and video versions of the same episode; it is not included as an attributed position or counted as separate views.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –PD-L1-positive PFS hazard ratios and p-values differ between some social accounts and the publication; the sources do not explain why.
• –Comments about PACIFIC-2, PACIFIC 6, DATE, COAST, CODE, I-SABR and other approaches retain their own population, timing and evidentiary limits and are not SKYSCRAPER-03 results.
• –No exact product-label source is available for atezolizumab or tiragolumab; no approval or label conclusion is drawn.

How reports are built and checked: Methods.

Last checked for new commentary Oct 31, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "SKYSCRAPER-03" (NCT04513925), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "skyscraper-03-04513925". If you cannot make requests, read https://www.erudio.com/reports/skyscraper-03-nct04513925.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT04513925", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct04513925 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/skyscraper-03-nct04513925.json
curl https://www.erudio.com/reports/skyscraper-03-nct04513925.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "skyscraper-03-04513925" })